Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Neoplasm Metastasis 1 Meningeal Neoplasms 1 Inhibition, Psychological 1 Hereditary Sensory and Autonomic Neuropathies 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Doxorubicin 27 Cyclophosphamide 26 Radiotherapy 16 Gemcitabine 16 Filgrastim 11 pembrolizumab 10 pazopanib 10 Radiation 9 Docetaxel 9 Cisplatin 9 fludarabine 7 Trabectedin 7 Ipilimumab 7 Ifosfamide 7 Granulocyte Colony-Stimulating Factor 7 Etoposide 7 Carboplatin 7 Busulfan 7 Bevacizumab 7 olaratumab 6 Temozolomide 6 Peripheral Blood Stem Cell Transplantation 6 Nivolumab 6 Mesna 6 Melphalan 6 selinexor 5 Leucovorin 5 Irinotecan 5 Celecoxib 5 Bortezomib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Sarcoma × AZD1390 × Clear all

NCT05116254 2026-01-23

SADDRIN-1

The Netherlands Cancer Institute

Phase 1 Terminated

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡